Blood tests to screen out the presence of amyloid and Alzheimer's disease

摘要

The invention comprises obtaining a blood or serum sample from a patient in a primary care setting; the following proteins: FABP, beta2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, α2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-α), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, I309, factor VII, Determining the expression level of at least four of the thymus and activation controlling chemokine (TARC), serum amyloid A (SAA), and intercellular cell adhesion molecule-1 (ICAM-1); Compared to statistical samples of a multi-ethnic, broad age range And the patient from the need for further analysis of Alzheimer's disease, including determining whether the patient will be excluded from further testing for Alzheimer's disease, thereby eliminating the need for further testing of the patient Including methods for excluding.